The Increasingly Critical Role of Optometrists in Neovascular Retinal Diseases

Release Date: May 31, 2023
Expiration Date: May 31, 2024
Time to Complete Activity: 1.0 hour

Faculty 

Roger A. Goldberg, MD, MBA
Vitreoretinal Specialist and Partner
Bay Area Retina Associates
Walnut Creek, CA
Faculty
California Pacific Medical Center Ophthalmology Residency
San Francisco, CA

Cecelia Koetting, OD, FAAO, DipABO
Optometrist
Koetting Consulting LLC
Englewood, CO

Target Audience 

This activity has been designed to address the educational needs of optometrists. It may also benefit other healthcare providers interested in the management of neovascular retinal diseases. 

Educational Provider 

This activity is provided by New England College of Optometry (NECO). 

Paradigm Medical Communications, LLC is the educational partner. 
 

Supporter Acknowledgment 

This activity is supported by an educational grant from Genentech, a member of the Roche Group.    

Program Overview 

Diagnosis and treatment of neovascular retinal diseases are evolving rapidly with the emergence of novel screening and monitoring tools and groundbreaking therapies. Because prompt detection and referral of these potentially blinding conditions are critical to preserving vision over time, optometrists’ early and ongoing involvement is essential to optimizing outcomes. This education will feature important advances in this field (including the recent availability of more durable treatment) that portend a greater role for optometrists in patient care.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Determine when referral to a retina specialist is warranted based on examination and imaging findings that suggest a need for treatment or additional assessment of neovascular retinal diseases 
  • Evaluate new techniques and technologies that can be used to diagnose and monitor neovascular retinal diseases
  • Describe data on novel therapies that increase comanagement opportunities for optometrists in neovascular retinal diseases

Optometrist Continuing Education

This activity, COPE Activity Number 126242, is accredited by COPE for continuing education for optometrists.

COPE Course ID: 84762-TD
COPE Activity ID: 126242

Please consult your state’s Board of Optometry to determine if the CE credit may apply toward your CE requirement for license renewal.

Instructions for Participation

In order to receive credit, participants must complete the activity in its entirety. Participants must also score at least 70% on the posttest and submit it, along with the credit application and evaluation form.

For information about the accreditation of this program, please contact NECO at 617-587-5648 or rosea@neco.edu

There are no fees for participating in this activity.

Hardware/Software Requirements

This accredited CE activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.

Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+

PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader

Technical Support

If you have any technical problems or playback issues, email us at contactus@paradigmmc.com.

Disclosure of Relevant Financial Relationships

In accordance with the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, NECO requires that all planners, faculty, and others who are in a position to control the content of this activity disclose all financial relationships with ineligible companies during the past 24 months.

All relevant relationships are identified and mitigated according to NECO policy prior to individuals assuming their roles, and are disclosed prior to learners’ engagement in the activity. NECO is committed to providing learners with high-quality accredited continuing education that promotes improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The content of this activity was vetted by NECO to ensure that it is fair and balanced, scientifically rigorous, evidence based, and aligned with the public interest. All relevant relationships have been mitigated. 

Roger A. Goldberg, MD, MBA
Consultant: AbbVie Inc; Apellis Pharmaceuticals, Inc; Boehringer Ingelheim International GmbH; Regeneron Pharmaceuticals, Inc
Research Funding: Annexon, Inc; Apellis Pharmaceuticals, Inc; Boehringer Ingelheim International GmbH; ZEISS International

Cecelia Koetting, OD, FAAO, DipABO
Consultant: Alcon Inc; Aldeyra Therapeutics, Inc; Allergan, Inc; Avellino, Inc; Bruder Healthcare Co; Claris Biotherapeutics, Inc; DOMPE; Eyevance/Santen; Glaukos Corporation; Kala Pharmaceuticals Inc; Orasis Pharmaceuticals; Oyster Point Pharma, Inc; RVL Pharmaceuticals, Inc; Sight Sciences, Inc; Tarsus Pharmaceuticals, Inc; Thea Pharma Inc; Visus Therapeutics
Speakers’ Bureau: Alcon Inc; DOMPE; Eyevance/Santen; Glaukos Corporation; Oyster Point Pharma, Inc; RVL Pharmaceuticals, Inc; Sight Sciences, Inc
Research Funding: Johnson & Johnson Services, Inc; Ocular Therapeutix, Inc; Tarsus Pharmaceuticals, Inc

NECO staff members have no relevant financial relationships with ineligible companies to disclose. 

Paradigm Medical Communications, LLC staff members have no relevant financial relationships with ineligible companies to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, NECO or Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.

Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CE activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC accepts no liability for the content referenced in this activity.

Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website”). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.

Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.

Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CE activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.

Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.

Contact Us

If you have any questions or comments, please email us at contactus@paradigmmc.com. 

© 2023 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.